APAC Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030

APAC Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Asia-Pacific Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type(Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application(Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the Rest of Asia-Pacific) Industry Trends and Forecast to 2030

Market Definition:

Pancreatic cancer is fatal, and the diagnosis process of pancreatic cancer also has safety issues; it is not cost-effective. One of the costliest medical disorders to treat is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their co-payment, deductible, and coinsurance costs are rising. Diagnosis of pancreatic cancer includes ultrasound, biopsy procedures and blood tests. Pancreatic cancer is one of the leading causes of death worldwide, and the prevalence of this disease has increased at an alarming rate.

Pancreatic cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Pancreatic cancer is the eighth most common cancer in women and the tenth most common cancer in men. Incidence rates of pancreatic cancer have gone up by around 1% each year. It occurs less frequently. It is slightly more common among women than men, however the average lifetime risk of getting pancreatic cancer in both sexes is about ½ of 1% on average. However, High cost associated with the treatment and diagnostic procedure is expected to restrain the market growth.

Market Segmentation:

The Asia-Pacific pancreatic cancer diagnostics market is segmented into eight notable segments based on test type, cancer stages, tumor type, product, application, technology, end user and distribution channel.
• On the basis of test type, the Asia-Pacific pancreatic cancer diagnostics market is segmented into imaging test, biopsy, blood test, genomic test, and others
• On the basis of cancer stages, the Asia-Pacific pancreatic cancer diagnostics market is segmented into stage 0, stage I, stage II, stage III and stage IV
• On the basis of tumor type, the Asia-Pacific pancreatic cancer diagnostics market is segmented into exocrine tumors and neuroendocrine tumors
• On the basis of product, the Asia-Pacific pancreatic cancer diagnostics market is segmented into instrument-based products, platform-based products, kits and reagents, and other consumables
• On the basis of technology, the Asia-Pacific pancreatic cancer diagnostics market is segmented into fluorescent in situ hybridization, next generation sequencing, fluorimmunoassay, comparative genomic hybridization, immunohistochemical, and others
• On the basis of application, the Asia-Pacific pancreatic cancer diagnostics market is segmented into screening, diagnostic and predictive, prognostic, and research
• On the basis of end user, the Asia-Pacific pancreatic cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and others
• On the basis of distribution channel, the Asia-Pacific pancreatic cancer diagnostics market is segmented into direct tender, retail sales and others

Market Players

Some of the major players operating in the Asia-Pacific pancreatic cancer diagnostics market are:
• Canon Medical Systems ANZ Pty Limited.
• Koninklijke Philips N.V.
• Siemens Healthcare Private Limited
• Myriad Genetics, Inc.
• BD
• Boditech Med Inc.
• Abbott
• Agilent Technologies, Inc.
• Thermo Fisher Scientific
• QIAGEN
• MP BIOMEDICALS
• Laboratory Corporation of America Holdings
• AccuBioTech Co., Ltd.
• Setia Scientific Solution
• Meridian Life Science, Inc.